Integra Lifesciences Holdings (IART) Other Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings (IART) has 17 years of Other Operating Expenses data on file, last reported at $178.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 6.88% year-over-year to $178.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 71.11% YoY), and the FY2025 full-year result was $1.3 billion, changed N/A from the prior year.
• Other Operating Expenses declined to $178.7 million in Q1 2026, from $217.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $721.4 million in Q2 2025 to a low of $644000.0 in Q3 2022.
• A 5-year average of $215.6 million and a median of $188.1 million in 2024 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses soared 380.0% in 2022 and decreased 6.88% in 2026, its largest moves.
• Tracing IART's Other Operating Expenses over 5 years: stood at $644000.0 in 2022, then jumped by 27425.93% to $177.3 million in 2023, then gained by 11.29% to $197.3 million in 2024, then rose by 10.41% to $217.8 million in 2025, then declined by 17.96% to $178.7 million in 2026.
• Business Quant data shows IART's Other Operating Expenses at $178.7 million in Q1 2026, $217.8 million in Q4 2025, and $198.8 million in Q3 2025.